The COPD treatment ‘Trelegy Ellipta’ has landed in general hospitals in Korea. The company has been making rapid entry into the market since its reimbursed release in June this year.

According to industry sources, GSK Korea’s triple inhaled therapy for COPD (Chronic Obstructive Pulmonary Disease), “Trelegy Ellipta (fluticasone·umeclidinium·vilanterol)" has passed the review of drug committees (DCs) of 50 medical institutions nationwide, including the ‘Big-5’ general hospitals of Korea - Samsung Medical Center, Seoul National University Hospital, St. Mary’s Hospital, Severance Hospital, and Seoul Asan Medical Center.

Trelegy Ellipta is the first triple combination therapy for COP